Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ ("CELZ-201-DDT").
https://finance.yahoo.com/news/creative-medical-technology-holdings-receives-120000984.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.